Rayya Fadi
General and HPB Surgery, Al Assad University Hospital, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic.
Case Rep Gastroenterol. 2021 Mar 11;15(1):296-304. doi: 10.1159/000513281. eCollection 2021 Jan-Apr.
Liver transplantation (LT) is the only curative therapy for the end-stage liver diseases and some metabolic disorders which affect the hepatic cell like the Crigler-Najjar syndrome type 1 (CNSI). Although the LT is a routine procedure in many centers worldwide, the postoperative complications such as rejection, arterial thrombosis, and infection remain serious challenges even in big centers. In our paper, we demonstrate the first two LTs in Syria. The first one was performed on 6 February 2016 for an 11-year-old boy suffering from CNSI using an auxiliary LT, but unfortunately, he had a hepatic artery and portal vein thrombosis, so we removed the necrotic graft on the fifth postoperative day, and he survived. The second LT was for a 9-year-old boy, who had cryptogenic liver cirrhosis, and he lived for 31 days after the transplantation. In both transplants, grafts were obtained from living relative donors.
肝移植（LT）是治疗终末期肝病和一些影响肝细胞的代谢紊乱疾病（如1型克里格勒 - 纳贾尔综合征（CNSI））的唯一治愈性疗法。尽管肝移植在全球许多中心都是常规手术，但即使在大型中心，术后并发症如排斥反应、动脉血栓形成和感染仍然是严峻挑战。在我们的论文中，我们展示了叙利亚的首例两例肝移植手术。第一例于2016年2月6日为一名患有CNSI的11岁男孩进行，采用辅助性肝移植，但不幸的是，他出现了肝动脉和门静脉血栓形成，因此我们在术后第五天切除了坏死的移植物，他存活了下来。第二例肝移植是为一名患有隐源性肝硬化的9岁男孩进行的，他在移植后存活了31天。两例移植手术的移植物均来自活体亲属供体。
